Clinical observation and mechanism of the elimination of HPV16/18/58 subtype infection and the reversal of grade I cervical intraepithelial neoplasia in Han Chinese women treated with modified Ermiao granules

Objective: To evaluate the efficacy and molecular mechanism of modified Ermiao granules in eliminating HPV16/18/58 subtype infection and reversing cervical intraepithelial neoplasia (CIN) I in Han Chinese women. Materials and methods: A total of 135 cases of CIN I with HPV16/18/58 infection from May 2016 to April 2019 were randomly and equally divided into three groups: control group, no treatment given; traditional Chinese medicine treatment group, treated with modified Ermiao granules; and interferon group, treated with recombinant human interferon α$\alpha$2b gel. Each group had 45 cases. The negative rate of HPV, CIN I reversal, the levels of CD3+, CD4+, CD8+, IgA, IgM, and IgG, the expression of TLR4, p16, and ki67, the amplification of hTERC, and the mRNA expression levels of P16 and Ki67 were compared. Result: Modified Ermiao granules and interferon could reduce the negative HPV rate, promote the CIN I course reversal, significantly decrease the TLR4, p16, and ki67 expression levels, and decrease the hTERC amplification. The difference among the three groups was statistically significant (P < 0.0167). The CD3+, CD4+, IgA, IgM, IgG, and CD8+ levels were significantly increased by modified Ermiao granules and interferon, and the P16 and Ki67 expression levels were significantly decreased (P < 0.05). Modified Ermiao granules had more obvious advantages in eliminating HPV, reversing CIN I, reducing TLR4 protein expression and hTERC amplification, and improving IgA, IgM, and IgG levels compared with those of the interferon group (P < 0.0167, P < 0.05). Conclusion: Modified Ermiao granules can improve the HPV clearance rate, reverse the CIN I course, inhibit cell proliferation, enhance cervical local immune function, and improve inflammatory stress level. Modified Ermiao granules has a good curative effect on HPV16/18/58 subtype infection and CIN I in Han Chinese women.

Human papilloma virus; Modified Ermiao granules; Cervical intraepithelial neo- plasia; Human telomerase RNA component

[1] Sundstrom B, Smith E, Delay C, Luque JS, Davila C, Feder B, et al. A reproductive justice approach to understanding women’s experiences with HPV and cervical cancer prevention. Social Science and Medicine. 2019; 232: 289–297.

[2] Hoffman SR, Le T, Lockhart A, Sanusi A, Dal Santo L, Davis M, et al. Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): a systematic review. International Journal of Cancer. 2017; 141: 8–23.

[3] Mittal S, Basu P, Muwonge R, Banerjee D, Ghosh I, Sengupta MM, et al. Risk of high-grade precancerous lesions and invasive cancers in high-risk HPV-positive women with normal cervix or CIN 1 at baseline-a population-based cohort study. International Journal of Cancer. 2017; 140: 1850–1859.

[4] Spriggs CC, Blanco LZ, Maniar KP, Laimins LA. Expression of HPV-induced DNA damage repair factors correlates with CIN progression. International Journal of Gynecological Pathology. 2019; 38: 1–10.

[5] Zhu Y, Han Y, Tian T, Su P, Jin G, Chen J, et al. MiR-21-5p, miR34a, and human telomerase RNA component as surrogate markers for cervical cancer progression. Pathology-Research and Practice. 2018; 214: 374–379.

[6] Zhou N, Fei D, Zong S, Zhang M, Yue Y. MicroRNA-138 inhibits proliferation, migration and invasion through targeting hTERT in cervical cancer. Oncology Letters. 2019; 12: 3633–3639.

[7] Zappacosta R, Ianieri MM, Buca D, Repetti E, Ricciardulli A, Liberati M. Clinical role of the detection of human telomerase RNA component gene amplification by fluorescence in situ hybridization on liquid-based cervical samples: comparison with hu- man papillomavirus-DNA Testing and histopathology. Acta Cytologica. 2015; 59: 345–354.

[8] Yu L, Fei L, Liu X, Pi X, Wang L, Chen S. Application of p16/Ki67 dual-staining cytology in cervical cancers. Journal of Cancer. 2019; 10: 2654–2660.

[9] van Zummeren M, Leeman A, Kremer WW, Bleeker MCG, Jenkins D, van de Sandt M, et al. Three-tiered score for Ki-67 and p16ink4a improves accuracy and reproducibility of grading CIN lesions. Journal of Clinical Pathology. 2018; 71: 981–988.

[10] Celewicz A, Celewicz M, Wężowska M, Chudecka-Głaz A, Menkiszak J, Urasińska E. Clinical efficacy of p16/Ki-67 dualstained cervical cytology in secondary prevention of cervical cancer. Polish Journal of Pathology. 2018; 69: 42–47.

[11] Chen L, Luan S, Xia B, Liu Y, Gao Y, Yu H, et al. Integrated analysis of HPV-mediated immune alterations in cervical cancer. Gynecologic Oncology. 2018; 149: 248–255.

[12] Paaso A, Jaakola A, Syrjänen S, Louvanto K. From HPV infection to lesion progression: the role of HLA alleles and host immunity. Acta Cytologica. 2019; 63: 148–158.

[13] Sun Y, Peng S, Qiu J, Miao J, Yang B, Jeang J, et al. Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors. Gene Therapy. 2016; 22: 528–535.

[14] Papasavvas E, Surrey LF, Glencross DK, Azzoni L, Joseph J, Omar T, et al. High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ARTsuppressed HIV-1-infected women. OncoImmunology. 2016; 5: e1128612.

[15] Ma L, Feng L, Ding X, Li Y. Effect of TLR4 on the growth of SiHa human cervical cancer cells via the MyD88-TRAF6-TAK1 and NF-κB-cyclin D1-STAT3 signaling pathways. Oncology Letters. 2018; 15: 3965–3970.